Mineralys CMO exercises options, sells 417 shares

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported a small, pre-planned stock transaction.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported a small, pre-planned stock transaction. He exercised stock options covering 417 shares of common stock at $15.44 per share and sold 417 common shares at $27.55 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 63,443 shares of common stock and 4,167 stock options, indicating this activity affected only a small portion of his overall position.

Insider Trade Summary 10b5-1

Exercise and Sale: 417 shares ($5K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 417 shs ($11K)

Approx. gross sale proceeds $11K

Approx. exercise cost $6K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Stock Option	417	$0.00	$0.00
Exercise	Common Stock	417	$15.44	$6K
Sale	Common Stock	417	$27.55	$11K

Holdings After Transaction: Stock Option — 4,167 contracts (Direct); Common Stock — 63,443 shares (Direct)

Footnotes (2)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold: 417 shares Sale price: $27.55 per share Options exercised: 417 shares +3 more

6 metrics

Shares sold 417 shares Open-market sale of common stock on May 18, 2026 at $27.55

Sale price $27.55 per share Price for 417 Mineralys common shares sold

Options exercised 417 shares Common stock acquired via option exercise at $15.44 per share

Exercise price $15.44 per share Conversion or exercise price of stock option into common stock

Shares held after 63,443 shares Direct Mineralys common stock holdings following reported transactions

Options remaining 4,167 options Stock options remaining after exercising 417 options; expiration March 17, 2033

Key Terms

Rule 10b5-1 trading plan, stock option, exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock option financial

"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Chief Medical Officer financial

"officer_title: Chief Medical Officer"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom report in this Form 4?

David Malcom reported exercising options for 417 Mineralys Therapeutics shares and selling 417 common shares. The transactions occurred on May 18, 2026, and were executed under a pre-established Rule 10b5-1 trading plan adopted on October 6, 2025.

How many Mineralys Therapeutics (MLYS) shares did David Malcom sell and at what price?

David Malcom sold 417 shares of Mineralys Therapeutics common stock at an average price of $27.55 per share. This open-market sale was reported as a non-derivative transaction code “S” and formed part of a pre-planned Rule 10b5-1 trading program.

What stock options did David Malcom exercise in Mineralys Therapeutics (MLYS)?

He exercised stock options covering 417 shares of Mineralys Therapeutics common stock at an exercise price of $15.44 per share. These options are part of a larger grant that vests 25% after one year, with the remainder vesting in 36 equal monthly installments.

How many Mineralys Therapeutics (MLYS) shares does David Malcom hold after these transactions?

After the reported transactions, David Malcom directly holds 63,443 shares of Mineralys Therapeutics common stock. He also retains 4,167 stock options, giving him continued equity exposure in addition to the shares he owns outright.

Were David Malcom’s Mineralys Therapeutics (MLYS) transactions under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans pre-schedule trades, making the timing more routine and less indicative of short-term views.

What does the vesting schedule of David Malcom’s Mineralys Therapeutics (MLYS) stock option look like?

The option vested 25% of its underlying shares on the first anniversary of the grant date. The remaining shares vest in 36 substantially equal monthly installments thereafter, creating a gradual, time-based vesting structure for Malcom’s equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/19/2026 - 07:15 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		M⁽¹⁾		417	A	$15.44	63,860	D
Common Stock	05/18/2026		S⁽¹⁾		417	D	$27.55	63,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$15.44	05/18/2026		M⁽¹⁾			417	⁽²⁾	03/17/2033	Common Stock	417	$0	4,167	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR